Welcome to our dedicated page for Pharming Group N.V. SEC filings (Ticker: PHAR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Pharming Group N.V. ADS (PHAR) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures, including Form 20‑F annual reports and Form 6‑K current reports. As a foreign private issuer listed on Nasdaq, Pharming uses these filings to communicate material information about its rare disease biopharmaceutical business, which centers on RUCONEST for hereditary angioedema (HAE) and Joenja (leniolisib) for activated phosphoinositide 3‑kinase delta syndrome (APDS).
Form 6‑K reports furnished by Pharming typically include press releases on quarterly and half‑year financial results, revenue trends for RUCONEST and Joenja, updates on clinical development of leniolisib in adult and pediatric APDS populations, and information on regulatory submissions and reviews in the U.S. and other jurisdictions. These filings may also cover organizational changes, index promotions on Euronext Amsterdam, and capital allocation or restructuring plans.
Form 20‑F annual reports (when available) provide a broader view of Pharming’s operations, risk factors, product portfolio, and financial statements, complementing the more event‑driven 6‑K disclosures. Together, these documents help investors understand how Pharming manages its rare disease pipeline, license agreements for leniolisib, and obligations such as milestones and royalties.
On Stock Titan, users can review Pharming’s SEC filings alongside AI‑generated highlights that summarize key points from lengthy documents, such as revenue drivers, segment performance, and major clinical or regulatory milestones. The filings page also surfaces insider and major shareholder transaction reports when available, allowing closer monitoring of ownership changes in PHAR. Real‑time updates from EDGAR ensure that new 6‑K or 20‑F submissions are quickly reflected, helping investors and analysts track Pharming’s evolving financial and clinical profile without manually searching the SEC’s database.
Pharming Group N.V. has begun an organizational restructuring designed to accelerate growth while cutting overhead. The company is redesigning its structure and reducing non-commercial and non-medical headcount by 20%, mainly at its Netherlands headquarters, as part of a previously announced general and administrative (G&A) expense reduction plan.
Pharming states it remains on track to lower total G&A expenses by 15%, or about US$10 million annually. The company expects one-time restructuring charges of roughly $7 million to be recorded in the fourth quarter of 2025 in connection with the headcount reduction.
Pharming Group announced the FDA has accepted its supplemental NDA seeking approval of leniolisib (Joenja) for children aged 4–11 with activated phosphoinositide 3-kinase delta syndrome (APDS). The application received Priority Review with a PDUFA target action date of January 31, 2026. The sNDA is supported by positive data from a multinational, single-arm Phase III study in 4–11-year-olds showing, over 12 weeks, reductions in lymphadenopathy and increases in naïve B cells, indicating correction of the underlying immune defect; the submission also included safety data from 8 months of treatment. There are no approved treatments globally for children under 12 with APDS. Leniolisib is already approved in the U.S. for patients aged 12 and older (March 2023).
Pharming Group N.V. filed a Form 6-K to report that it has been promoted from the Euronext AScX (Small Cap) to the Euronext AMX (MidCap) index, effective September 22, 2025. The AMX index includes 25 companies selected by Euronext Amsterdam based on free-float market capitalization and liquidity, and this move marks Pharming’s return to the AMX.
The company describes this promotion as a reflection of its strong financial and pipeline growth momentum and expects AMX inclusion to increase its visibility and attractiveness to investors. Management reiterates its focus on executing commercial and pipeline catalysts as it aims to develop further as a global rare disease company.
Pharming Group announced the appointment of Kenneth Lynard as Chief Financial Officer, effective October 1, 2025. The release states Mr. Lynard has over 20 years of global finance leadership in life sciences, including recent CFO roles at Schoeller Allibert and Zentiva and senior finance roles at Gilead Sciences where he served as Senior Vice President and CFO for Global Commercial Operations, R&D and Manufacturing.
The company frames the hire as strengthening financial leadership following strong first half 2025 financial results and supporting Pharming's growth strategy and commercial and pipeline catalysts. Mr. Lynard holds an MSc in Business Economics and Auditing and an executive MBA from IMD.